Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Vertex Pharmaceuticals (VRTX)

Vertex Q1 2026 revenue rises 8% to $2.99 billion; 2026 guidance reiterated

Positive Impact 3 of 5 earnings Written later

Vertex reported first quarter 2026 total revenue of $2.99 billion, up 8% from the prior-year quarter, and GAAP net income of $1.0 billion versus $646 million a year earlier. The company reiterated its full year 2026 total revenue guidance of $12.95 billion to $13.1 billion, which signals no change to its outlook for shareholders.

Key points

  • Total revenue of $2.99 billion, up 8%; U.S. revenue rose 7% to $1.78 billion and outside the U.S. rose 9% to $1.21 billion
  • GAAP diluted EPS of $4.02 versus $2.49; non-GAAP diluted EPS of $4.47 versus $4.06
  • First quarter 2025 GAAP results included a $379.0 million intangible asset impairment charge
  • Full year 2026 total revenue guidance of $12.95 billion to $13.1 billion reiterated, unchanged

The filing

CompanyVertex Pharmaceuticals (VRTX)
Form8-K, current report
Filed with the SECMay 4, 2026, 4:05 PM ET
Accession number0000875320-26-000171

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.